Comparative Study
doi: 10.1016/0022-4731(86)90318-3.
Aromatase inhibitors and benign prostatic hyperplasia
- PMID: 2433507
- DOI: 10.1016/0022-4731(86)90318-3
Item in Clipboard
Comparative Study
Aromatase inhibitors and benign prostatic hyperplasia
J Steroid Biochem.
1986 Nov.
Abstract
A growing amount of evidence implies that estrogens may play a role together with androgens in the genesis of benign prostatic hyperplasia (BPH) in man. We review here some of this evidence together with advances made in characterizing inhibitors of estrogen biosynthesis (aromatase inhibitors). It is proposed that aromatase inhibitors may find application in non-surgical treatment of BPH.
Similar articles
-
Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):565-72. doi: 10.1016/0960-0760(93)90260-4. J Steroid Biochem Mol Biol. 1993. PMID: 7682838 Review.
-
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):557-63. doi: 10.1016/0960-0760(93)90259-y. J Steroid Biochem Mol Biol. 1993. PMID: 7682837 Review.
-
Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.J Androl. 1991 Nov-Dec;12(6):395-402. J Androl. 1991. PMID: 1722796 Review.
-
Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.Prostate. 1986;8(2):181-94. doi: 10.1002/pros.2990080208. Prostate. 1986. PMID: 2419882
-
The function and the role of aromatase inhibitors in the treatment of BPH.Prog Clin Biol Res. 1994;386:209-30. Prog Clin Biol Res. 1994. PMID: 7528389 Review. No abstract available.
Cited by
-
Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.Molecules. 2020 Jan 9;25(2):265. doi: 10.3390/molecules25020265. Molecules. 2020. PMID: 31936496 Free PMC article. Review.
-
The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.Br J Cancer. 1988 Feb;57(2):190-2. doi: 10.1038/bjc.1988.40. Br J Cancer. 1988. PMID: 3358910 Free PMC article.
-
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.Br J Cancer. 1992 Jul;66(1):139-42. doi: 10.1038/bjc.1992.231. Br J Cancer. 1992. PMID: 1637664 Free PMC article. Clinical Trial.
-
Aromatase inhibition in advanced prostatic cancer: preliminary communication.Br J Cancer. 1990 Aug;62(2):275-6. doi: 10.1038/bjc.1990.276. Br J Cancer. 1990. PMID: 2201397 Free PMC article. Clinical Trial.
-
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.Rev Urol. 2006 Fall;8(4):183-9. Rev Urol. 2006. PMID: 17192797 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical